TIL
Instil Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.68
+0.26%Aug 13, 2026, 00:00 UTC
Instil Bio reported a Q2 2026 net loss of $4.3 million, or $0.63 per diluted share, with total cash, cash equivalents, restricted cash and marketable securities of $69.9 million as of June 30, 2026, expected to fund operations beyond 2027.